Physician profile
Eric E Born
NPI 1386653913
$21,396.85
in general payments reported to CMS, 2019-2025
68 companies · $2,826 in 2025
The $2,826 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,260 · 2020: $3,299 · 2021: $3,398 · 2022: $2,953 · 2023: $2,898 · 2024: $2,762 · 2025: $2,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,478 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,477.93 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,500.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,297.90 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,824.12 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $1,245.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,244.28 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $1,056.77 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $937.02 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $918.23 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $896.90 | 2019-2022 | |
| Glaxosmithkline, LLC. | $858.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $821.61 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $580.88 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $525.34 | 2019-2020 | |
| Corcept Therapeutics | $479.00 | 2020-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $459.79 | 2019-2023 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Born listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.